Bridging the Gap: Conference Workbook [International Conference on AIDS (12th: 1994: Geneva, Switzerland)]

~~-* -~ ---~-~-PL-i*rl---iui~il~i~'l`l~111^~~-~
Wednesday, July 1

ORAL S SSIO SD1.0-2.31.0 -1.3

B31 Clinical and Virologic Manifestation 1
of HIV-infection
Chairs: Sushma Sengupta, Marcio Soares Serra
Venue: Session Hall III
Time: 11.00-12.30
333 Primary HIV-1 infection: Clinical manifestations among 12186
women in Mombasa, Kenya
Ludo Lavreys*; H. Martin; K. Manoaliya;J. Bwayo;
J. Nainya-Achola;J. Kreiss, Kenya
334 Complete HIV pol sequence in plasma and genital tract 32279
of women: Genital reservoir and differential drug resistance
Guowei Fang*; H. Burger; K. Anastos; C Chappey; D. Mayers;
W Meyer; B. Weiser, USA
335 Repertoire of chemokine receptor expression in the female genital 21109
tract: Progesterone increases CCR5, CXCR4, and CCR3 expression
Bruce Patterson*;A. Landay;. Andersson; H. Behbahani;
M.A. Czerniewski; Z. Burki; P Garcia, USA
336 Alterations in bodyfatdistribution in HIV-infected men and women 32173
Donald P Kotler*;K.B. Rosenbaum; J. Wang; R.N. Pierson, r., USA
337 Determinants of increased energy expenditure in 32162
HIV-infected women
Steven K. Grinspoon, USA
338 Immunologic function and reconstitution in HIV-infected 31186
patients on highly active antiretroviral therapy (HAART)
lYana Fogelman*; VJ. Davey; M. Sneller; M.B. Feinberg;
H.D. Ochs; J.P Siegel; H.C. Lane, USA
B32 Clinical Immunology in HIV-1 Infection
Chairs: Adriano Lazzarin, Kiat Ruxrungtham
Venue: Session Hall VII
Time: 11.00-12.30
339 Triple combination therapy and change in peripheral blood 41178
T-cell subset composition during asymptomatic HIV-infection
Leslie R. Bisset*; Milos Opravil; R. Con; W Huber; M. Battegay;
P Vernazza; RJ. Grob; R. Luethy, Switzerland
340 Immune restoration disease after treatment of immuno- 22323
deficient HIV-infected patients with potent antiretroviral therapy
Martyn French*; N. Lenzo; M. John; S. Mallal; P Price;
J. Flexman, Australia
341 Extended benefit of protease inhibitor-containing combination 12101
therapy through a dissociated viremia-CD4 T cell response
Daniel Kaufmann*; Giuseppe Pantaleo; Pascal Meylan;
Philippe Sudre; Patrick Francioli; Micheal P Glauser;
Amalio Telenti, Switzerland
342 Discrepant immunologic and virologic responses in 32259
HIV-infected patients receiving triple combination therapy
Christophe Piketty*; P Castiel; L. Belec; L. Weiss; J.P Abouker;
M.D. Kazatchkine, France
343 IL2 in HIV patients: A randomized trial comparing 41229
SC, PEG, CIV IL2 with AZT+ddl
Yves Levy*; C Capitant; S. Houhou; I. Carriere;J.A. Gaustaut;
J.P. Viard; J.P. Aboulker, France
344 Long-term follow-up of an early HIV-infected cohort receiving 41230
intermittent outpatient treatment with subcutaneous
interleukin-2 (sclL-2)
Richard Davey, Jr.*; D.G. Chaitt; J.A. Kovacs; R.E. Walker;
J. Falloon; M.A. Polls; H.C. Lane, USA

B33 Current Limits and Future of ART
Chairs: Ibrahim Ndoye,EricVan Praag
Venue: Arena
Time: 11.00-12.30
347 Barriers to therapeutic effectiveness of ART
Claudia Brabazon
348 Issues in clinical management in middle income settings
Pedro Cahn
349 Implications of ART use in resource-poor settings
Elly Katabira
350 The future of HIV therapy
Daniel Kuritzkes
C31 Forecasting and Determinants
Chairs: Ronald Brookmeyer, Kofi Awusabo-Asare
Venue: Session Hall V
Time: 11.00-12.30
351 Forecasting the global pandemic: use and misuse of data
Tim Brown
352 Epidemic determinants and dynamics in Africa
To be announced
353 Concepts and models: sexual networks and population groups
Richard Rothenberg
354 Cost and impact of interventions on epidemic dynamics
Charlotte Watts
C32 Local Policies, National Issues, Global Impact Q
Chairs: Dennis P.Altman, Rao Prasad
Venue: Session Hall VI
Time: 11.00-12.30
355 HIV/AIDS policy in Brazil 43560

Richard G. Parker*;J. Galvao, USA
356 Setting performance standards for a national HIV prevention
program
David R. Holtgrave*; S. Pinkerton, USA
357 A public health approach to move HIV prevention research
to practice
Jane Mezoff*; E. Sogolow; L.S. Doll; S. Semaan; M.S. Neumann;
J.R. Anderson, USA
358 Medical supply for HIV/AIDS in developing countries:
Thailand experience
Chaiyos Kunanusont*; P Satasit; W Phoolcharoen, Thailand
359 Enhancing training capacities through regional military
networking in countries of Eastern and Southern Africa
Joyce Chiluba Puta, Zambia
360 Integrating AIDS prevention into family planning program in
southern Yunnan, China
Zunyou Wu*;J.P.Zhang; C.M. Wang; L.L. Dong;X.Q. Bi;
S. Duan; Z.R. Li, China

43500
43218
43506
43391
13403

345 Changes in lymphocyte subsets with interleukin-2 therapy 22412
in patients with advanced HIV disease on highly active
antiretroviral therapy (HAART)
Daniel Berger*; B.E. Baker; G. Bucher; R. Bessinger; P Maroni;
W.M. Reiter, USA
346 In vivo persistence of genetically modified, HIV-1-specific 42322
syngeneic lymphocytes in HIV-1-discordant identical twins
Robert Walker*; C.M. Bechtel; V Natarajan; R.M. Blaese; K.M. Hege;
M.R. Roberts; H.C Lane, USA
Pathway Symbols: 0 Gender
124

Policy

12th World AIDS Conference Geneva